Objective: To verify the efficacy and safety of the new combination of Tanacetum parthenium 150 mg, 5-hydrossitriptophan (5-HTTP) 20 mg and magnesium 185 mg (Aurastop®) in the prophylactic treatment of episodic migraine without aura (MO). Methods: Eighty patients suffering from MO for at least 6 months with a monthly frequency of 3 to 8 attacks and 4 to12 headache days, were enrolled in this open study and treated with Aurastop twice daily per os for 3 months. The reduction of headache days per month was assessed as the primary end-point, while the secondary end-points were: 1) reduction of the number of MO attacks; 2) reduction of intensity of the pain; 3) reduction of acute treatment drug intake; 4) subjective change of pain intensity. Results: All the parameters significantly improved at the end of the observational period of treatment with Aurastop.
Introduction
Neurological disorders are considered as the principal cause group of disability-adjusted life years; among them, migraine ranked as the second most frequent condition [1] ; epidemiologic studies have consistently indicated its prevalence being up to 18% among women and 6% among men in Western Countries, with the peak reached between 22 and 55 years [2] , and a high impact in terms of social and economic costs [3] . In Italy, the direct and indirect costs of migraine have been estimated to be about 6 billion Euros per year.
To reduce the global impact of migraine, it is generally accepted that a prophylactic treatment should be started in patients who present disabling migraine attacks for at least 4 days per month, and/or in the case of inefficacy of appropriate symptomatic approaches.
The main purpose of migraine prophylaxis is to reduce the frequency of attacks, the number of headache day per month, the patient disability, and consequently to improve the quality of life. A prophylactic therapy is considered effective when it reduces the frequency of migraine attacks of at least 50%.
According to national and international therapeutic guidelines, first-line drugs for migraine prophylaxis include beta-blockers, calcium antagonists, anti-depressants, anti-epileptics, onabotulinumtoxinA and phytotherapics plus magnesium [4] .
However, a number of migraineurs are unsatisfied from the standard prophylactic drugs because of the lack of efficacy and/or side effects; in these cases, nutraceuticals could be proposed for migraine prevention.
The term "nutraceutical", a blend of the words "nutrition" and "pharmaceutical", was coined by DeFelice in 1989 and indicates a food or a part of food that has beneficial health effects and could be used in the prevention or treatment of a disease.
In the last years the use of nutraceuticals products by migraine has increased as reported by the National Health Interview study [5] ; according to the results of this survey, 49.5% of the patients use nutraceutical products without informing their health care providers.
Recently, Scientific Societies have reviewed the principal studies published on the topic with the aim to update the therapeutical guidelines and, if the case, insert nutraceuticals for migraine prevention according to their level of evidence [6] . 
Material and Methods
Eighty patients with episodic migraine as defined by the International Classification of Headache Disorders 3 beta (ICHD 3 beta) [7] were consecutively recruited from January 2017 to the end of the year, among those referring to the Criteria for patients selection were: 1) age between 18 and 65 years; 2) diagnosis of MO, according to the ICHD 3 beta diagnostic criteria; 3) migraine for at least 6 months with a monthly crisis frequency ranging from 3 to 10; 4) headache duration ranging from 4 to 12 days per month. Psychiatric co-morbidity, other types of acute or chronic pain, kidney failure, neurological or oncologic diseases, and pregnancy were considered as exclusion criteria.
A preventative treatment had been started before the beginning of the survey and was continued during the study in 5 cases (propranolol 40 mg tablet bid since 2 months: n = 2; amitriptyline 12 drops since 1 month: n = 2; onabotuli-numtoxinA: 1 session of 31 injection as for PREEMPT study n = 1).
At baseline evaluation all patients underwent a thorough a neurological examination and were carefully instructed on how to record MO attacks in their headache diary on a day-to-day basis. In particular, during the observational period of three months they were asked to register: 1) attacks frequency; 2) pain intensity (using the VAS scale, ranging from 1 to 10); 3) duration; 4) response to analgesics, based on a self-rate scale ranging between 1 (minimum response) and 5 (maximum response). At the end of the screening phase, diary cards were controlled and the eligible patients received Aurastop® (a combination of Tanacetum parthenium 150 mg, 5-hydrossitriptophan (5-HTTP) 20 mg and magnesium 185 mg) twice daily for 3 months. Safety was evaluated by treatment discontinuation rate and the occurrence of serious and otherwise adverse events.
The primary endpoint of the study was the reduction of headache days per month. The secondary endpoints were: 1) reduction of MO attacks; 2) reduction of intensity of the pain; 3) reduction of acute treatment drugs intake; 4) subjective change of pain intensity. 
Statistical Analysis

Results
Overall, 80 patients (35 males, 45 females; mean age: 37.5 years, range 19 -60) were enrolled in the study. One patient withdrew after 1 month of treatment because of lack of improvement and one was lost to follow-up.
The results of the analysis are summarized in Table 1 . that show a significant reduction of the number of headache days (from 9.1 ± 2.0 before treatment to 
Discussion
The mechanisms of action of nutraceuticals in migraine prevention could be hypothesised on the basis of pre-clinical observations, that demonstrated their effects on the vessel wall, neurons, and specific neurotransmitters involved in the pathophysiology of migraine. Albeit evidences suggest the role of the cerebrovascular system as well as an abnormal cortical activity and immunological involvement, the exact pathophysiology of migraine remains not completely Parthenolide could modulate mast cells activation by the inhibition of the IκB kinase complex (IKK)β, which is involved in the proinflammatory cytokine-mediated signaling. Furthermore, parthenolide interacts with the TRPA1 nucleophilic sites. The antimigraine effect of parthenolide could derive both from its partial agonism on TRPA1 and the inhibition of CGRP release obtained by desensitization and nociceptor defunctionalization [5] [6] [8] . Glutamate is another neuropeptide likely involved in migraine pathogenesis due to its excitatory effect on first and second order neurons and its role in the activation of the trigeminovascular system. Moreover, the post-synaptic glutamatergic receptor N-methyl-D-Aspartate (NMDA) is involved on the occurrence of both central sensitization and cortical spreading depression, as demonstrated by its activation during migraine attacks [9] . NMDA receptors are activated by an increase of the synaptic levels of glutamate and inhibited by magnesium [10] [11] [12] .
Glutamate levels are regulated by kynurenine [13] which metabolizes l-triptophan in kynurenic acid (KYNA) and quinolinic acid (QUINA). In particular, the NMDA receptor antagonist KYNA inhibits glutamatergic pathway by blocking glutamate release and neurotransmission through its action on the binding site of glycin Glu N1. Recently, it has been observed that in migraineurs the kynuretic pathway is shifted towards the conversion of KYNA in antralinic acid (ANA); this observation is supported by the finding of elevated plasma levels of ANA, which has also a direct neurotoxic effect through the release of free radicals, and reduced concentration of KYNA and QUINA, leading to a subsequent loss of inhibitory control on glutamate and its excitatory effects.
Low plasma levels of KYNA may be considered a reliable marker of NMDA receptor activation, while its cerebral levels can be increased by the assumption of its precursor 5-HTP [14] . If used as a drug, this latter may, therefore, increase KYNA levels inhibit peripheral NMDA receptors and subsequently prevent the activation of the trigeminovascular system and the onset of CSD. These findings are most similar to that emerged from a similar previous study of Merlo, P. [15] , even if with a smaller group of patients, and of the first study using Aurastop of Zavarise, P. [16] to testify the efficacy of this combination of molecules.
These findings lead to the speculation that the 3 molecules in combination might act synergistically on different pathways involved in migraine biology: 
Conclusion
In spite of the methodological limitations of this observational pilot study due to the absence of a placebo group, our findings emphasize the potential effect of Aurastop® on the complex physiopathological mechanisms of migraine and confirmed our previous observation [15] . The combination Tanacetum parthenium + 5-HTP + magnesium appears to be a promising alternative therapy for migraine prophylaxis with an excellent safety profile. Further clinical trials are needed in order to investigate its potentials in preventing migraine, either alone or in combination with other molecules.
